title: Startle and sensorimotor gating in rats lacking CCK-A receptors.
abstract: Otsuka Long Evans Tokushima Fatty (OLETF) rats lack CCK-A receptors because of a genetic mutation. Previous studies have shown that CCK-A receptors seem to play a role in the regulation of prepulse inhibition (PPI) of the startle reflex, an operational measure of sensorimotor gating. This study investigated baseline and drug-disrupted PPI in OLETF rats and their non-mutant counterparts, Long Evans Tokushima Otsuka (LETO) rats. Baseline PPI did not differ significantly between the two rat genotypes but OLETF rats exhibited a higher acoustic startle response compared to LETO rats. Amphetamine (2 mg/kg), and the non-competitive NMDA antagonist, dizocilpine (0.1 mg/kg), disrupted PPI in LETO rats but not in the OLETF rats. Apomorphine (0.5 mg/kg) failed to disrupt PPI in both LETO and OLETF rats, and haloperidol (0.5 mg/kg) produced a comparable facilitation of PPI in both groups. In a separate study, OLETF rats were found to be less sensitive to the locomotor stimulating effects of amphetamine. These results suggest that CCK-A receptors play a significant role in the behavioral effects of amphetamine and dizocilpine. The PPI response of OLETF rats to amphetamine and dizocilpine is similar to normal rats pretreated with atypical antipsychotics, suggesting that CCK-A receptors may play an important role in the restoration of drug-disrupted PPI by antipsychotics.
authors.affiliation: Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093-8218, USA. dfeifel@ucsd.edu
authors.forename: D
authors.initials: D
authors.lastname: Feifel
authors.forename: K
authors.initials: K
authors.lastname: Priebe
authors.forename: P D
authors.initials: PD
authors.lastname: Shilling
mesh_terms: D000161:Acoustic Stimulation / Q000009:adverse effects; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D002766:Cholecystokinin / Q000235:genetics* / Q000378:metabolism; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000235:genetics; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D020334:Rats, Inbred OLETF / Q000033:anatomy & histology / Q000378:metabolism*; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000172:deficiency* / Q000187:drug effects / Q000235:genetics*; D013216:Reflex, Startle / Q000187:drug effects / Q000502:physiology*
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018691:Excitatory Amino Acid Antagonists; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D016291:Dizocilpine Maleate; D002766:Cholecystokinin; D000661:Amphetamine; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine